CSIMarket
 


Pmv Pharmaceuticals Inc   (PMVP)
Other Ticker:  
 
 

PMVP's Income from Cont. Operations Growth by Quarter and Year

Pmv Pharmaceuticals Inc 's Income from Cont. Operations results by quarter and year




PMVP Income from Cont. Operations (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - -18.36 8.76 0.00
III Quarter September -18.23 -15.01 -8.76 0.00
II Quarter June -17.31 -12.87 0.00 0.00
I Quarter March -18.43 -11.60 0.00 0.00
FY   -53.97 -57.84 0.00 0.00



PMVP Income from Cont. Operations third quarter 2022 Y/Y Growth Comment
Pmv Pharmaceuticals Inc in the third quarter 2022 recorded loss from continued operations of $ -18.23 millions.

According to the results reported in the third quarter 2022, Pmv Pharmaceuticals Inc achieved the best Income from Cont. Operations growth in Major Pharmaceutical Preparations industry. While Pmv Pharmaceuticals Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the third quarter 2022.




PMVP Income from Cont. Operations ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Pmv Pharmaceuticals Inc 's third quarter 2022 Income from Cont. Operations $ -18.23 millions PMVP's Income Statement
Pmv Pharmaceuticals Inc 's third quarter 2021 Income from Cont. Operations $ -15.01 millions Quarterly PMVP's Income Statement
New: More PMVP's historic Income from Cont. Operations Growth >>


PMVP Income from Cont. Operations (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Pmv Pharmaceuticals Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PMVP's III. Quarter Q/Q Income from Cont. Operations Comment
Recent results of -18.23 millions by Pmv Pharmaceuticals Inc appear even more unfavourable if you take a look at -17.31 millions in the previous quarter.

Within Major Pharmaceutical Preparations industry Pmv Pharmaceuticals Inc achieved highest sequential Income from Cont. Operations growth. While Pmv Pharmaceuticals Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PMVP's III. Quarter Q/Q Income from Cont. Operations Comment
Current accomplishment of -18.23 millions by Pmv Pharmaceuticals Inc look even less good compare to the loss from continued operations -17.31 millions a quarter before.

Within Major Pharmaceutical Preparations industry Pmv Pharmaceuticals Inc achieved highest sequential Income from Cont. Operations growth. While Pmv Pharmaceuticals Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Pmv Pharmaceuticals Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
Cumulative Income from Cont. Operations 12 Months Ending $ -72.33 $ -69.11 $ -64.68 $ -57.85 $ -30.72
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Pmv Pharmaceuticals Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -72 millions in the Sep 30 2022 period.
The situation is detiriorating as the cumulative loss from continued operations is becoming larger from $ -69.11 millions for the period from Jun 30 2022 to Sep 30 2021 and $ -17.31 millions for the twelve months ending in the quarter a year ago Donelle Torres told.

Pmv Pharmaceuticals Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
Pmv Pharmaceuticals Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -72 millions in the Sep 30 2022 period.
The business is getting worse as the cumulative loss from continued operations is becoming larger from $ -69.11 millions in TTM ending quarter Jun 30 2022 and $ -17.31 millions for the twelve months ending in the quarter a year ago Donelle Torres told.

Pmv Pharmaceuticals Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
PMVP's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for PMVP's Competitors
Income from Cont. Operations Growth for Pmv Pharmaceuticals Inc 's Suppliers
Income from Cont. Operations Growth for PMVP's Customers

You may also want to know
PMVP's Annual Growth Rates PMVP's Profitability Ratios PMVP's Asset Turnover Ratio PMVP's Dividend Growth
PMVP's Roe PMVP's Valuation Ratios PMVP's Financial Strength Ratios PMVP's Dividend Payout Ratio
PMVP's Roa PMVP's Inventory Turnover Ratio PMVP's Growth Rates PMVP's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Sep 30 2022
Medpace Holdings Inc 35.93%$ 35.931 millions
Zimmer Biomet Holdings Inc 33.20%$ 33.196 millions
Iradimed Corporation33.03%$ 33.026 millions
Eli Lilly And Company30.77%$ 30.772 millions
Bio techne Corp30.09%$ 30.085 millions
Merit Medical Systems Inc27.62%$ 27.618 millions
Abbvie Inc 24.28%$ 24.277 millions
Repligen Corp20.62%$ 20.619 millions
Ensign Group Inc16.34%$ 16.337 millions
Integra Lifesciences Holdings Corp15.47%$ 15.466 millions
Amgen Inc 13.75%$ 13.747 millions
Viatris Inc 13.74%$ 13.740 millions
Corcept Therapeutics Inc13.39%$ 13.386 millions
Prestige Consumer Healthcare Inc 12.06%$ 12.063 millions
Assertio Holdings inc 11.69%$ 11.694 millions
Syneos Health Inc 11.25%$ 11.255 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

MMS's Profile

Stock Price

MMS's Financials

Business Description

Fundamentals

Charts & Quotes

MMS's News

Suppliers

MMS's Competitors

Customers & Markets

Economic Indicators

MMS's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071